Publication Name	World Journal of Hepatology
Manuscript ID	77104
Country	Belgium

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Study
Article Title	Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma
Manuscript Source	Unsolicited Manuscript
All Author List	Nika De Wilde, Luisa Vonghia, Sven Francque, Thomas De Somer, Ali Bagdadi, Eva Staub, Jasper Lambrechts, Ana-Maria Bucalau, Gontran Verset and Christophe Van Steenkiste
Funding Agency and Grant Number
Corresponding Author	Gontran Verset, MMed, Doctor, Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, Brussels 1070, Belgium. gontran.verset@erasme.ulb.ac.be
Key Words	Advanced hepatocellular carcinoma; Systemic treatment; Immunotherapy; Nivolumab; Difficult-to-treat patients; Real-life setting
Core Tip	We conducted a study on the real-world effectiveness of nivolumab (immunotherapy) in patients with advanced liver cancer who were ineligible for the standard of care or other validated treatments, including patients with impaired liver function and a poor general condition, a population that is usually not included in studies. We showed a reduction of tumor mass in 24.1% of patients, with a disappearance of tumor mass in 13.9% of patients, which is better than that reported in the literature. Furthermore, we confirmed the favorable safety profile of nivolumab. Hence, nivolumab should be considered as a valuable treatment option in selected patients who are otherwise not eligible for treatment.
Citation	De Wilde N, Vonghia L, Francque S, De Somer T, Bagdadi A, Staub E, Lambrechts J, Bucalau AM, Verset G, Van Steenkiste C. Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma. World J Hepatol 2022; 14(8): 1608-1620

Received	2022-04-15 13:24
Peer-Review Started	2022-04-15 13:25
To Make the First Decision
Return for Revision	2022-05-12 08:25
Revised	2022-05-27 14:15
Second Decision	2022-07-29 02:49
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-08-01 04:51
Articles in Press	2022-08-01 04:51
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-08-02 09:40

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com